Stockwinners Market Radar for October 29, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. General Motors has agreed to a $13.9M settlement with Orange County, California over claims accusing the automaker of intentionally concealing serious safety defects including those involving faulty ignition switches tied to hundreds of deaths and injuries, according to Reuters. 2. Celgene (CELG) has announced that its Ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator, demonstrated superiority versus Biogen's (BIIB) Avonex in the phase III RADIANCE Part B trial evaluating the efficacy and safety in patients with relapsing multiple sclerosis. 3. Target's (TGT) missteps have cost the company $15B in stock-market value over the past three years, Vito Racanelli wrote in this week's edition of Barron's. But the retailer is now remodeling stores, cutting costs and ramping up its online business to combat Amazon (AMZN), and store traffic and earnings look poised to rise in coming years, which could lead to an upward revaluation of the shares, he noted, adding that the stock could return up to 30%. 4. Lionsgate's (LGF.A) "Jigsaw" slayed the competition at the domestic box office, ending the weekend with an estimated $16.3M from 2,941 theaters. Despite having said "Saw 3D" back in 2010 would be the final chapter in the "Saw" series, Lionsgate decided to have another go, with the new movie picking up a decade after the death of the killer when police are puzzled by a rash of murders matching his signature moves. "Jigsaw" earned a B CinemaScore and got 39% from Rotten Tomatoes. 5. Amgen (AMGN), Biogen, Celgene, Gilead Sciences (GILD), Enterprise Products Partners (EPD), Amazon, Alphabet (GOOGL; GOOG), and Microsoft (MSFT), Alibaba (BABA), China Life Insurance (LFC), and Sony (SNE) saw positive mentions in Barron's.

19:11 EDT Switching data in patients with Crohn's supports use of Pfizer INFLECTRA - New data show that switching patients with Crohn's disease, or CD, to INFLECTRA from REMICADE led to comparable efficacy, safety and tolerability to treatment with REMICADE over a 24-week period. The full 54-week results of the randomized controlled trial comparing INFLECTRA and REMICADE in biologic-naive patients with active CD support the long-term effectiveness of treatment with INFLECTRA. The results also show that INFLECTRA was well-tolerated, with a similar safety profile to REMICADE. Pfizer and Celltrion Healthcare jointly announced the secondary outcomes from the phase III trial of INFLECTRA in CD at the 25th United European Gastroenterology Week. The study previously reported its primary endpoint at six weeks, demonstrating non-inferiority of INFLECTRA compared to REMICADE in the treatment of CD. More than 50 real-world studies in IBD have been conducted with INFLECTRA, evaluating over 7,500 IBD patients in real-world settings. There is an important and growing body of evidence for the switching of stable REMICADE patients to INFLECTRA. Clinical studies supporting this switch include NOR-SWITCH,15 BIO-SWITCH,16 PROSIT-BIO3 and now CT-P13 3.4.

18:30 EDT Pluristem proposes to launch public offering of common stock - Pluristem has announced that in connection with its proposed public offering of its shares of Common Stock on the Tel Aviv Stock Exchange, or TASE, it has concluded an Israeli institutional investors tender. In the tender the company has received overall commitments from Israeli institutional investors and accredited investors for the purchase of 8,873,700 shares in different prices for a total amount of approximately $15M and chose to accept commitments of 7,123,700 shares at a purchase price of $1.61 for a total amount of approximately $11.5M. Upon the approval of the TASE, the company intends to conduct a public offering of its shares on the TASE on Monday, October 30, 2017 at a minimum purchase price of $1.61, for up to 9,000,000 shares in the aggregate. The company has engaged Leader Underwriters as its advisor for the offering. Leader is not purchasing or selling any of the shares offered in the offering in its capacity as an advisor nor is Leader required to arrange for the sale of any specific number or dollar amount of securities, but has agreed to use its best efforts to arrange for the sale of the securities offered. The closing of the offering is expected to occur on or about October 31, 2017, subject to customary closing conditions. The company intends to use the net proceeds of the offering for research and product development activities, clinical trial activities, investment in capital equipment and for working capital and other general corporate purposes. In order to participate in the public offering, prospective investors should place orders through their brokers.

10:08 EDT Enzymotec enters definitive agreement to be acquired by Frutarom - Enzymotec has announced that it has signed a definitive agreement under which Frutarom will acquire Enzymotec for $11.90 per share in cash. The transaction will be completed by way of a merger under the Israeli Companies Law. The transaction has received unanimous approval by Enzymotec's Board of Directors and implies an equity value of approximately $290M. The offer of $11.90 per share in cash represents a premium of 39.8% over the price of Enzymotec's ordinary shares on the Nasdaq Stock Market on July 31, 2017, the date on which Frutarom first disclosed an ownership position in Enzymotec. A shareholder meeting to approve the transaction is expected to be held in December 2017. Assuming typical timeframes, Enzymotec currently anticipates the transaction will close in the first quarter of 2018.

10:01 EDT Global Blood announces presentation of case study in sickle cell disease - Global Blood Therapeutics has announced the presentation of a case study in which a patient with sickle cell disease who was ineligible to participate in its ongoing Phase 3 HOPE study of voxelotor due to severe, transfusion-refractory anemia received the investigational agent through single-patient compassionate access. Details of the patient's medical history and the clinical course observed with voxelotor were delivered in an oral presentation at the Sickle Cell Disease Association of America 45th Annual National Convention in Atlanta. The case study involved a 67-year-old male with HbSS sickle cell genotype with severe anemia refractory to transfusion due to red cell antibodies that developed following multiple blood transfusions. These antibodies prevented further transfusions to correct his anemia. He also had moderate chronic obstructive pulmonary disease requiring supplemental oxygen therapy, recurrent and frequent pain exacerbations, extreme fatigue and clinical depression. After receiving voxelotor 900 mg orally once daily, the patient showed a rapid response, with an improvement in pain, fatigue, and overall mental health. His hemoglobin levels rose quickly to approximately 1.5 g/dL above baseline with a sustained increase over 66 weeks in range of 1 to 1.5 g/dL. Reductions occurred in reticulocyte count and bilirubin, both consistent with diminished hemolysis. Blood oxygen saturation improved on standard walk test, from 86mmHg at baseline to 96mmHg at 65 weeks, and he discontinued continuous oxygen supplementation. No hospitalization prompted by sickle cell pain has occurred since voxelotor initiation. His sole treatment-related side effect, Grade 2 diarrhea, occurred nine weeks after starting voxelotor treatment when the dose was increased to 1,500 mg daily, but resolved upon return to 900 mg with no further treatment-related side effects. Clinical and laboratory improvements have continued for more than 17 months and he remains on treatment today under compassionate use access.